Clinical Analysis of Octreotide in the Treatment of Liver Cirrhosis with Upper Gastrointestinal Hemorrhage
This paper study the clinical effect of octreotide in the treatment of cirrhosis with upper gastrointestinal hemorrhage.A total of 90 patients with cirrhosis and upper gastrointestinal hemorrhage treated in our hospital from January 20167 to January 2018 were randomly divided into two groups: the observation group and the control group, with 45 cases in each group. The control group was treated with pituitrin and the observation group was treated with octreotide. The hemostasis time, treatment effect and adverse reaction rate of the two groups were compared. In the observation group, 30 patients with hemostasis within 24 ± 1.0 hours, 9 patients with hemostasis within 72 ± 2.0 hours, 4 patients with hemostasis after 72 hours, and 2 patients without hemostasis were significantly better than those in the control group (P < 0.05); in the observation group, 43 (95.56) patients with effective rate were significantly higher than those in the control group (P < 0.05); in the observation group, 4 (8.89) patients with adverse reactions were significantly lower than those in the control group (P < 0.05). The difference was statistically significant.In the treatment of liver cirrhosis and upper gastrointestinal bleeding patients, octreotide has significant effect. The patients have faster hemostasis, higher treatment efficiency, lower adverse reaction rate, significantly improve the hemostasis rate and reduce the mortality rate. It is worth popularizing and applying clinically.